#Oncology #Immunotherapy #TIGIT #Cancer #TherapeuticCombination #NKCell #TLymphocyte #PredictiveBiomarker
Immunotherapy has
revolutionized cancer treatment by leveraging the immune system to fight tumor
cells. However, despite its successes, it often faces resistance that limits
its effectiveness, particularly in advanced cancers. Among the mechanisms of
tumor immune evasion, the role of
TIGIT (T-cell immunoreceptor with Ig and ITIM
domains) has garnered increasing attention.
TIGIT is an inhibitory
molecule expressed on
T lymphocytes and NK cells, two essential players in the
anti-tumor immune response. TIGIT interacts with ligands such as CD155, which
are widely expressed on tumor cells and their microenvironment. This
interaction
inhibits T cell activation and reduces NK cells' ability to destroy cancer
cells. As a result, tumors evade immune surveillance, promoting their growth
and spread. TIGIT acts as an immunological brake, interacting with ligands like
CD155 to suppress immune cell activation. Its increased expression in the tumor
environment fosters immunosuppression and tumor progression.
TIGIT is an inhibitory
molecule
expressed on T lymphocytes and NK cells, two pillars of the anti-tumor
immune response. By binding to its ligand CD155, which is abundantly present on
tumor cells and their microenvironment, TIGIT
blocks T cell activation and
limits NK cell cytotoxicity. This immunosuppressive mechanism allows tumors to
escape immune surveillance, promoting their proliferation and dissemination.
The increased expression of TIGIT in the tumor environment acts as a powerful
immunological brake, reinforcing
tumor progression.
This pathway has
emerged as a key therapeutic target in onco-immunology. By targeting TIGIT, it
becomes possible to reactivate these immune cells and restore their ability to
recognize and eliminate cancer cells, offering a promising new approach to overcoming
current immunotherapy limitations.
Read next: CD47: The Tumor Shield Finally Broken?
TIGIT: The New Key
to Boosting Immunotherapy?
To understand the role
of TIGIT and its ligand in tumor immune evasion,
murine models and
human tumor
samples were selected and analyzed. The selection and study of phase I and II
clinical trials enabled the characterization of the
efficacy of anti-TIGIT
monoclonal antibodies (e.g., tiragolumab and vibostolimab), either alone or in
combination with PD-1/PD-L1 inhibitors. The effectiveness of these therapies
was assessed by evaluating the following outcome variables:
objective response
rate, overall survival, and
progression-free survival. At the same time,
toxicity profiles were analyzed to measure the risks associated with these
therapies. Finally, the study explored the effects of
therapeutic combinations
aimed at optimizing immune responses and overcoming
tumor resistance.
These studies
demonstrate that
TIGIT blockade effectively restores the antitumor activity of
T lymphocytes and NK cells, enhancing their ability to detect and destroy tumor
cells. In animal models, this approach
significantly reduces tumor growth.
Clinically, trials combining anti-TIGIT antibodies, such as tiragolumab, with
immune checkpoint inhibitors like PD-1/PD-L1 blockers have shown encouraging
results. These findings are particularly significant in non-small cell lung
cancer (NSCLC) and melanoma. Such combination therapies
improve overall
survival and progression-free survival while
strengthening immune responses.
Although the data remain preliminary, they suggest significant potential for
patients with advanced or resistant cancers.
TIGIT: A New Hope
for Immunotherapy
Cancer remains one of
the leading causes of mortality worldwide. Despite advances in immunotherapy,
many patients develop resistance to existing treatments. Identifying
new immune
targets is therefore essential to
improving the management of advanced and
resistant cancers.
This study explored
the role of TIGIT in tumor immune evasion and evaluated the efficacy of
anti-TIGIT therapies, alone or in combination with PD-1/PD-L1 inhibitors. The
objective was to analyze their impact on immune cell activation and patient
survival while identifying the most promising approaches to optimize their
effectiveness.
The results show that
TIGIT blockade can
enhance antitumor immunity and improve treatment responses.
Clinical trials combining anti-TIGIT antibodies with other immunotherapies,
particularly PD-1/PD-L1 inhibitors, suggest a
potential benefit in terms of survival
and tumor control. However, these therapies are not effective in all patients,
highlighting the need for better patient selection.
Future research should
refine therapeutic combinations and
identify predictive biomarkers to better
target patients. Combining anti-TIGIT therapies with other immune strategies
could offer an effective alternative for resistant cancers and promote more personalized
immunotherapy. Additionally, the
long-term safety and tolerance of these
treatments must still be evaluated on a larger scale to ensure their safety.
Read next: HER2, the key to revolutionizing cancer treatment
